Rapid early onset lymphocyte cell death in mice resistant, but not susceptible to Leishmania major infection

Apoptosis

Volumn 5, Issue 2, 2000, Pages 189-196

  Desbarats, Julie ^a,d   Stone, Jeffrey E ^a   Lin, Lin ^b   Zakeri, Zahra F ^b   Davis, Gerald S ^a   Pfeiffer, Linda M ^a   Titus, Richard G ^c   Newell, M Karen ^a,d  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b CITY UNIVERSITY OF NEW YORK   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

Apoptosis; Cell death; Fas (CD95); Leishmania; Lymphocytes; T cell; Th1; Th2

Indexed keywords

FAS ANTIGEN;

APOPTOSIS; ARTICLE; CELL DEATH; CYTOKINE RELEASE; LEISHMANIA MAJOR; LEISHMANIASIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD95; APOPTOSIS; DISEASE SUSCEPTIBILITY; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNITY, NATURAL; IN SITU NICK-END LABELING; LEISHMANIA MAJOR; LEISHMANIASIS, CUTANEOUS; LYMPH NODES; LYMPHOCYTES; MICE; MICE, INBRED BALB C; MICE, INBRED CBA; SPLEEN;

ANIMALIA; LEISHMANIA MAJOR;

EID: 0034044816     PISSN: 13608185     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009601200580     Document Type: Article

References (47)

1. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, Modlin RL. Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 1993; 91: 1390-1395.
2. Louzir H, Melby PC, Ben Salah A, et al. Immunologic determinants of disease evolution in localized cutaneous leishmaniasis due to Leishmania major. J Infect Dis 1998; 177: 1687-1695.
3. Bogdan C, Rollinghoff M. The immune response to Leishmania: Mechanisms of parasite control and evasion. Int J Parasitol 1998; 28: 121-134.
4. Mosmann TR. Regulation of Immune Responses by T cells with different cytokine secretion phenotypes: role of a new cytokine, cytokine synthesis inhibitory factor (IL10). International Archives of Allergy & Applied Immunology 1991; 94: 110-115.
5. Scott P. Differentiation, regulation, and death of T helper cell subsets during infection with Leishmania major. Immunol Res 1998; 17: 229-238.
6. Reiner SL, Locksley RM. The Regulation of Immunity to Leishmania Major. Ann Rev Immunol 1995; 13: 151-177.
7. Solbach W, Lohoff M, Streck H, Rohwer P, Rollinghoff M. Kinetics of cell-mediated immunity developing during the course of Leishmania major infection in "healer" and "non-healer" mice: Progressive impairment of response to and generation of interleukin-2. Immunol 1987; 62: 485-492.
8. Weintraub J, Gottlieb M, Weinbaum FI. Leishmania tropica: Association of a B-cell mitogen with hypergammaglobulinemia in mice. Exp Parasitol 1982; 53: 87-94.
9. Milon G, Titus RG, Cerottini J-C, Marchal G, Louis JA. Higher frequency of Leishmania major specific L3T4 + T cells in susceptible BALB/c as compared with resistant CBA mice. J Immunol 1986; 136: 1467-1471.
10. Heinzel FP, Sadick MD, Holaday BJ, Coffman RL, Locksley RM. Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets. J Exp Med 1989; 169: 59-72.
11. Howard JG. Immunological regulation and control of experimental leishmaniasis. Int Rev Exp Path 1986; 28: 79-116.
12. Liew FY, O'Donnell CA. Immunology of leishmaniasis. Adv Parasitol 1993; 32: 102-259.
13. Sadick MD, Heinzel FP, Holaday BJ, Pu RT, Dawkins RS, Locksley RM. Cure of murine leishmaniasis with anti-interleukin 4 monoclonal antibody. Evidence for a T cell dependent, interferon gamma-independent mechanism. J Exp Med 1990; 171: 115-127.
14. Scott P, Natovitz P, Coffman RL, Pearce E, Sher A. Immunoregulation of cutaneous leishmaniasis. T cell line that transfer protective immunity or exacerbation belongs to different T helper subsets and respond to distinct parasite antigens. J Exp Med 1996; 168: 1675-1684.
15. Wang ZE, Reiner SL, Zheng S, Dalton DK, Locksley RM. CD4+ effector cells default to the Th2 pathway in interferon gamma deficient mice infected with Leishmania major. J Exp Med 1994; 179: 1367-1371.
16. Shankar A, Titus RG. T cell and non-T cell compartments can independently determine resistance to Leishmania major. J Exp Med 1995; 181: 845-855.
17. Noben-Trauth N, Kropf P, Muller I. Susceptibility to Leishmania major infection in Interleukin-4-Deficient Mice. Science 1996; 271: 987-990.
18. Huang F-P, Xu D, Esfandiari E-O, Sands W, Wei X-q, Liew FY. Mice defective in Fas are highly susceptible to Leishmania major infection despite elevated IL-12 synthesis, strong Th1 responses, and enhanced nitric oxide production. J Immunol 1998; 160: 4143-4147.
19. Conceicao-Silva F, Hahne M, Schroter M, Louis J, Tschopp J. The resolution of lesions induced by Leishmania major in mice requires a functional Fas (APO-1, CD95) pathway of cytotoxicity. Eur J Immunol 1998; 28: 237-245.
20. Murphy ML, Engwerda CR, Gorak PM, Kaye PM. B7-2 blockade enhances T cell responses to Leishmania donovani. J Immunol 1997; 159: 4460-4469.
21. Corry DB, Reiner SL, Linsley PS, Locksley RM. Differential effects of blockade of CD28-B7 on the development of Th1 or Th2 effector cells in experimental leishmaniasis. J Immunol 1994; 153: 4142-4148.
22. Vieira LQ, Goldschmidt M, Nashleanas M, Pfieffer K, Mak T, Scott P. Mice lacking the TNF receptor p55 fail to resolve lesions caused by Infection with Leishmania major, but control parasite replication. J Immunol 1996; 157: 827-835.
23. Zhou T, Edwards CK, Yang P, Wang Z, Bluethmann H, Mountz JD. Greatly acclerated lymphadenopathy and autoimmune diseasee in lpr mice lacking tumor necrosis factor receptor I. J Immunol 1996; 156: 2661-1665.
24. Sytwu HK, Liblau RS, McDevitt HO. The roles of Fas/APO-1 (CD95) and TNF in antigen-induced programmed cell death in T cell receptor transgenic mice. Immunity 1996; 5: 17-30.
25. Moore KJ, Matlashewski G. Intracellular infection by Leishmania donovani inhibits macrophage apoptosis. J Immunol 1994; 152: 2930-2937.
26. Zhang X, Brunner T, Carter L, et al. Unequal death in Th1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis. J Exp Med 1998; 185: 1837-1849.
27. Zhang X, Giangreco L, Broome HE, Dargen CM, Swain SL. Control of CD4 effector fate: TGFb1 and IL-2 synergize to prevent apoptosis and promote effector expansion. J Exp Med 1995; 185: 699-709.
28. Swain SL, Croft M, Dubey C, et al. From naive to memory T cells. Immunol Rev 1996; 150: 143-167.
29. Vella AT, Dow S, Potter TA, Kappler J, Marrack P. Cytokine-induced survival of activated T cells in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 3810-3815.
30. Vella A, Teague TK, Ihle J, Kappler J, Marrack P. Interleukin 4 (IL-4) or IL-7 prevents the death of resting T cells: stat6 is probably not required for the effect of IL-4. J Exp Med 1997; 186: 325-330.
31. Foote LC, Marshak-Rothstein A, Rothstein TL. Tolerant B lymphocytes acquire resistance to Fas-mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen unless a surface immunoglobulin threshold is exceeded. J Exp Med 1998; 187: 847-853.
32. Foote LC, Howard RG, Marshak-Rothstein A, Rothstein TL. IL-4 induces Fas resistance in B cells. J Immunol 1996; 157: 2749-2753.
33. Zamorano J, Wang HY, Wang LM, Pierce JH, Keegan AD. IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. J Immunol 1996; 157: 4926-4934.
34. Arkins S, Rebeiz N, Brunke-Reese DL, Biragyn A, Kelley KW. Interferon-gamma inhibits macrophage insulin-like growth factor-I synthesis at the transcriptional level. Mol Endocrinol 1995; 9: 350-360.
35. Buck M, Houglum K, Chojkier M. Tumor necrosis factor-alpha inhibits collagen alpha1(I) gene expression and wound healing in a murine model of cachexia. Am J Pathol 1996; 149: 195-204.
36. Cooney R, Iocono J, Maish G, Smith JS, Ehrlich P. Tumor necrosis factor mediates impaired wound healing in chronic abdominal sepsis. J Trauma 1997; 42: 415-420.
37. Shi Z, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. Proc Natl Acad Sci USA 1997; 94: 10663-10668.
38. Varga J, Jimenez SA. Modulation of collagen gene expression: its relation to fibrosis in systemic sclerosis and other disorders. Ann Int Med 1995; 122: 60-62.
39. Hubner G, Brauchle M, Smola H, Madlener M, Fassler R, Werner S. Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokine 1996; 8: 548-556.
40. Nestel FP, Price KS, Seemayer TA, Lapp WS. Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease. J Exp Med 1992; 175: 405-413.
41. Probert L, Akassoglou K, Kassiotis G, Pasparakis M, Alexopoupos L, Kollias G. TNF-alpha transgenic and knockout models of CNS inflammation and degeneration. J Neuroimmunol 1997; 72: 137-141.
42. Isomaki P, Punnonen J. Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 1997; 29: 499-507.
43. Titus RG, Ceredig R, Cerotinni J, Louis JA. Therapeutic effect of anti-L3T4 monoclonal antibody GK 1.5 on cutaneous leishmaniasis in genetically susceptible BALB/c mice. J Immunol 1985; 135: 2108-2114.
44. Swihart K, Fruth U, Messmer N, et al. Mice from a genetically resistant background lacking the interferon gamma receptor are susceptible to infection with Leishmania major but mount a polarized T helper cell 1-type CD4+ T cell response. J Exp Med 1995; 181: 961-971.
45. Titus RG, Lima GC, Engers HD, Louis JA. Exacerbation of murine cutaneous leishmaniasis by adoptive transfer of parasite-specific helper T cell populations capable of mediating Leishmania major-specific delayed type hypersensitivity. J Immunol 1984; 133: 1594-1600.
46. Ahuja HS, Zhu Y, Zakeri Z. Association of cyclin-dependent kinase 5 and its activator p35 with apoptotic cell death. Develop Genet 1997; 21: 258-207.
47. Zakeri ZF, Ahuja HS. Apoptotic cell death in the limb and its relationship to pattern formation. Biochem Cell Biol 1994; 72: 603-613.